Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Mycobacterium tuberculosis remains one of the most significant causes of death from an infectious agent. The rapid diagnosis of tuberculosis and detection of rifampin (RIF) resistance are essential for early disease management. The GeneXpert MTB/RIF assay is a novel integrated diagnostic device for the diagnosis of tuberculosis and rapid detection of RIF resistance in clinical specimens. We determined the performance of the MTB/RIF assay for rapid diagnosis of tuberculosis and detection of rifampin resistance in smear-positive and smear-negative pulmonary and extrapulmonary specimens obtained from possible tuberculosis patients. Two hundred fifty-three pulmonary and 176 extrapulmonary specimens obtained from 429 patients were included in the study. One hundred ten (89 culture positive and 21 culture negative for M. tuberculosis ) of the 429 patients were considered to have tuberculosis. In pulmonary specimens, sensitivities were 100% (27/27) and 68.6% (24/35) for smear-positive and smear-negative specimens, respectively. It had a lower sensitivity with extrapulmonary specimens: 100% for smear-positive specimens (4/4) and 47.7% for smear-negative specimens (21/44). The test accurately detected the absence of tuberculosis in all 319 patients without tuberculosis studied. The MTB/RIF assay also detected 1 RIF-resistant specimen and 88 RIF-susceptible specimens, and the results were confirmed by drug susceptibility testing. We concluded that the MTB/RIF test is a simple method, and routine staff with minimal training can use the system. The test appeared to be as sensitive as culture with smear-positive specimens but less sensitive with smear-negative pulmonary and extrapulmonary specimens that include low numbers of bacilli.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In lymph node biopsies, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (27 to 40) and 85% (73 to 93) (Sarfaraz 2018) and 76% (50 to 93) and specificity of 100% (66 to 100) (Zeka 2011) (2 studies; 288 participants); Figure 14.”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Zeka 2011
In the citing paper
“In lymph node biopsies, Xpert MTB/RIF sensitivity and specificity against a composite reference standard were 33% (27 to 40) and 85% (73 to 93) (Sarfaraz 2018) and 76% (50 to 93) and specificity of 100% (66 to 100) (Zeka 2011) (2 studies; 288 participants); Figure 14.”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Zeka 2011
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309 · cited 1×
“9% in cases of smear-negative, culture-positive pulmonary tuberculosis and 98 to 100% in cases of smear-positive, culture-positive pulmonary tuberculosis, while the test specificity remained at 99% to 100% (2, 4, 5, 9, 14).”
BackgroundDetection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337 · cited 1×
“tuberculosis strains have a mutation within the 81-bp hot spot region of the rpoB gene (6, 15, 18).”
BackgroundSusceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes
Woods, G. L., Brown‐Elliott, B. A., Conville, P. S., Desmond, E. P., Hall, G. S., Lin, G., Pfyffer, G. E., Ridderhof, J. C., Siddiqi, S. H., Wallace, R. J., et al. (2011) · Cited by 1,136
Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013 · cited 1×
“9% in cases of smear-negative, culture-positive pulmonary tuberculosis and 98 to 100% in cases of smear-positive, culture-positive pulmonary tuberculosis, while the test specificity remained at 99% to 100% (2, 4, 5, 9, 14).”
BackgroundHelb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914 · cited 6×
“A previous study found that the MTB/RIF assay had a calculated limit of detection of 131 CFU/ml of sputum and was able to detect as few as 10 CFU/ml of sputum in 35% of samples (9).”
BackgroundMethodInfluentialEvaluation of the analytical performance of the Xpert MTB/RIF assay
Blakemore, R., Story, E., Helb, D., Kop, J., Banada, P., Owens, M. R., Chakravorty, S., Jones, M., & Alland, D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00128-10 · Cited by 485 · cited 3×
“The assay can generally be completed in less than 2 h (3, 9).”
BackgroundMethodPublic Health Mycobacteriology
Kent, P. (1985) · Medical Entomology and Zoology · Cited by 328
Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis
(2009) · JAMA · doi:10.1001/jama.2009.148 · Cited by 268
Marlowe, E. M., Novak-Weekley, S. M., Cumpio, J., Sharp, S. E., Momeny, M. A., Babst, A., Carlson, J. S., Kawamura, M., & Pandori, M. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02214-10 · Cited by 253 · cited 1×
“9% in cases of smear-negative, culture-positive pulmonary tuberculosis and 98 to 100% in cases of smear-positive, culture-positive pulmonary tuberculosis, while the test specificity remained at 99% to 100% (2, 4, 5, 9, 14).”
BackgroundHillemann, D., Weizenegger, M., Kubica, T., Richter, E., & Niemann, S. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.3699-3703.2005 · Cited by 209 · cited 1×
“Molecular assays have been established to allow the prediction of drug resistance in clinical specimens within 1 working day and are potentially the most rapid methods for the detection of drug resistance (3, 6, 7, 9, 10, 11, 13, 15).”
Method
Research works printed but not linked: 1
- Tuberculosis Service. 2009. Tuberculosis report in Turkey. Ministry of Health, Ankara, Turkey.
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Chakravorty, S., Simmons, A. M., Rowneki, M., Parmar, H., Cao, Y., Ryan, J., Banada, P. P., Deshpande, S., Shenai, S., Gall, A., et al. (2017) · mBio · doi:10.1128/mbio.00812-17 · Cited by 668
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
A systemic review on tuberculosis
Natarajan, A., Beena, P. M., Devnikar, A. V., & Mali, S. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.02.005 · Cited by 397
Metadata
- Authors
- Zeka, A. N., Tasbakan, S., & Cavusoglu, C.
- Affiliations
- Ege University (TR)
- Chest Diseases Department, Faculty of Medicine, Ege University, Izmir, Turkey
- Mycobacteriology Laboratory, Medical Microbiology Department, Faculty of Medicine, Ege University Izmir, Turkey
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-12
- Volume
- 49
- Issue
- 12
- Pages
- 4138-4141
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC3232962
- OpenAlex
- W2028219354
- Semantic Scholar
- b3755ed80ed38de476ca9ade7b9cbb183cee5d5a
- Cited by
- 362
- References
- 18
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 19 · 2023: 27 · 2022: 30 · 2021: 40 · 2020: 24 · 2019: 37 · 2018: 42 · 2017: 29 · 2016: 30 · 2015: 26 · 2014: 15 · 2013: 12 · 2012: 7
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ege Üniversitesi
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Keywords
- Xpert MTB/RIF, tuberculosis diagnosis, rifampicin resistance, Mycobacterium tuberculosis, extrapulmonary tuberculosis, pulmonary tuberculosis, diagnostic sensitivity, rapid molecular detection, drug susceptibility testing
- MeSH terms
- Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Tuberculosis, Molecular Diagnostic Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens. https://app.cochat.ai/papers/10.1128/jcm.05434-11
- The paper
- Zeka, A. N., Tasbakan, S., & Cavusoglu, C. (2011). Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.05434-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.